Trial Profile
Randomised, Double Blind, Placebo Controlled Study of Lu AA24493 in Patients With Friedreich's Ataxia to Evaluate Safety and Tolerability and to Explore Efficacy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lu AA 24493 (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions; Biomarker
- Sponsors Lundbeck A/S
- 21 Apr 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
- 08 Jun 2011 Planned end date changed from 1 May 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov
- 15 Mar 2011 Planned end date changed from 1 Mar 2011 to 1 May 2011 as reported by ClinicalTrials.gov.